Aurobac Therapeutics SAS, a biopharmaceutical company founded by Boehringer Ingelheim Pharma GmbH & Co KG, Biomérieux SA and Evotec SE, has announced its strategy to target bacterial infections, antimicrobial resistance and their consequences in acute hospital settings, such as hospital-acquired and ventilator-associated bacterial pneumonia and sepsis.